Biomarin, Ascendis Reach Mutually Beneficial Agreement Ending Global Patent Disputes - BioMarin Pharmaceu
BioMarin (BMRN) and Ascendis (ASND) settled global patent disputes over Yuviwel. Ascendis will pay BioMarin 20% royalties on U.S. sales and 18% on EU, Brazil, and South Korea sales until 2030. Ascendis gains full license to BioMarin's Yuviwel patents. Ascendis expects 500M euros in 2026 operating cash flow and 5B euros in 2030 revenue. Yuviwel Q2 2026 revenue was 8M euros. ASND shares were down 0.21%, BMRN up 3.33% in premarket trading.
How this was made
The 30-second read
Why it matters
Both companies gain clarity; BioMarin adds royalty revenue, Ascendis secures licensing.
Market read
Settlement removes legal uncertainty, potentially supporting stock stability and modest upside.
What to watch
Future regulatory scrutiny of Yuviwel in other regions could affect cash flows.
Background
The settlement ends global patent disputes between BioMarin and Ascendis over the achondroplasia drug Yuviwel.
Ticker impact
BioMarin will receive a 20% US royalty and an 18% EU royalty from Ascendis under the new settlement.
Modest upside as market prices in the royalty benefit.
Royalty income adds incremental cash flow; market may price in the settlement quickly.
Ascendis secures a full license to BioMarin patents and agrees to pay royalties on Yuviwel sales.
Limited downside as royalty expense is offset by cleared IP hurdles.
The settlement clears litigation risk, likely stabilizing the stock.
Market effects
Biotech IP settlements may ease investor concerns across rare‑disease space.
US and EU markets see reduced litigation risk for the two firms.
Limited to companies involved; no broad market shift.
Counterpoint
Royalty payments could erode Ascendis margins more than anticipated.
Key entities
- companyBioMarin Pharmaceutical Inc.
US biotech developing rare‑disease therapies.
- companyAscendis Pharma A/S
Danish biotech commercializing Yuviwel.
